. 2017 Jul 17;10(6):1434–1440. doi: 10.1111/1751-7915.12754

Table 1.

Vaccine induced protection in lung or spleen after M. bovis aerosol infection

Vaccine	Lung (log₁₀) CFUs	Spleen (Log₁₀) CFUs
BCG	4.83 ± 0.09 (−1.35)^b	3.86 ± 0.05 (−0.98)^b
rec Rv1626	6.22 ± 0.24 (+0.04)^a	4.90 ± 0.12 (+0.06)^a
Rv1626 beads	5.70 ± 0.04 (−0.48)^ab	4.73 ± 0.08 (−0.11)^a
Cpe‐Rv1626 beads	6.07 ± 0.09 (−0.12)^a	4.72 ± 0.03 (−0.12)^a
CS.T3‐Rv1626 beads	6.46 ± 0.38 (+0.28)^a	5.06 ± 0.23 (+0.22)^a
DDA	6.18 ± 0.37^a	4.84 ± 0.19^a

Mean count ± standard error of the mean (group mean‐DDA group mean). Female C57BL/6 mice (eight per group) were vaccinated once by the subcutaneous route with BCG Pasteur 1173P2 (10⁶ CFUs per animal) or three times at 9 day intervals with either soluble recombinant Rv1626 (rec Rv1626) or beads formulated with the adjuvant DDA (1.25 mg ml⁻¹) or DDA alone (control group). Six weeks after the last vaccination, mice were aerosol challenged with M. bovis 83/6235 in a Madison chamber (calibrated to deliver 50 bacteria into the lungs) and five weeks later, euthanized and lungs and spleens homogenized and cultured. After three weeks of incubation, colonies were counted. Data were analysed using a Dunn's test of multiple comparisons following a significant Kruskal–Wallis test. Statistical significance is shown using a letter based system. Significantly different groups have different letters, and groups with means not significantly different share the same letter (P < 0.01).